Publicaciones en colaboración con investigadores/as de Aristotle University of Thessaloniki (13)

2023

  1. European Glaucoma Society - A guide on surgical innovation for glaucoma

    British Journal of Ophthalmology, Vol. 107, Núm. Suppl 1, pp. 1-114

  2. Patient-reported burden and overall impact of dry eye disease across eight European countries: a cross-sectional web-based survey

    BMJ Open, Vol. 13, Núm. 3

2022

  1. Evaluation of a Novel Αb Εxterno MicroShunt for the Treatment of Glaucoma

    Advances in Therapy, Vol. 39, Núm. 9, pp. 3916-3932

2021

  1. The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability

    Expert Opinion on Drug Safety, Vol. 20, Núm. 4, pp. 453-466

2020

  1. Novel Insights into the Transmission of SARS-CoV-2 Through the Ocular Surface and its Detection in Tears and Conjunctival Secretions: A Review

    Advances in Therapy, Vol. 37, Núm. 10, pp. 4086-4095

2019

  1. Role of corneal nerves in ocular surface homeostasis and disease

    Acta Ophthalmologica, Vol. 97, Núm. 2, pp. 137-145

2018

  1. Controlled Adverse Environment Chambers in Dry Eye Research

    Current Eye Research, Vol. 43, Núm. 4, pp. 445-450

2017

  1. Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting

    Ocular Surface

  2. Visual acuity and quality of life in dry eye disease: Proceedings of the OCEAN group meeting

    Ocular Surface

2016

  1. 24-h Efficacy of Glaucoma Treatment Options

    Advances in Therapy, Vol. 33, Núm. 4, pp. 481-517

  2. Erratum to: 24-h Efficacy of Glaucoma Treatment Options (Adv Ther, 10.1007/s12325-016-0302-0)

    Advances in Therapy

  3. Revisiting the vicious circle of dry eye disease: A focus on the pathophysiology of meibomian gland dysfunction

    British Journal of Ophthalmology, Vol. 100, Núm. 3, pp. 300-306

2007

  1. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension

    European Journal of Ophthalmology, Vol. 17, Núm. 2, pp. 183-190